Information Provided By:
Fly News Breaks for May 3, 2019
AGIO
May 3, 2019 | 05:34 EDT
Piper Jaffray analyst Tyler Van Buren lowered his price target for Agios Pharmaceuticals to $85 from $100 after Tibsovo sales came in below expectations for Q1. However, the analyst says this appears to be due to seasonality and that the strength of the underlying commercial efforts gives him confidence that the launch will return to its original trajectory. Van Buren keeps an Overweight rating on Agios shares.
News For AGIO From the Last 2 Days
There are no results for your query AGIO